Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy

INTRODUCTION: Current treatment regimens for multidrug-resistant tuberculosis (MDR-TB) are long, poorly tolerated and have poor outcomes. Furthermore, the costs of treating MDR-TB are much greater than those for treating drug-susceptible TB, both for health service and patient-incurred costs. Urgent...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMJ Open
Autors principals: Sweeney, Sedona, Gomez, Gabriela, Kitson, Nichola, Sinha, Animesh, Yatskevich, Natalia, Staples, Suzanne, Moodliar, Ronelle, Motlhako, Sharon, Maloma, Matshepo, Rassool, Mohammed, Ngubane, Nosipho, Ndlovu, Ella, Nyang'wa, Bern-Thomas
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2020
Matèries:
Health Economics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7549492/
https://ncbi.nlm.nih.gov/pubmed/33039989
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2019-036599
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars